Table 1.
Current clinical trials utilizing the NKG2D stress response pathway.
| Study Title | Disease Targeted | Therapeutic Approach | Clinical Trials Identifier |
|---|---|---|---|
| NKG2D-based CAR T-cells Immunotherapy for Patient with r/r NKG2DL+ Solid Tumors | Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer | Autologous genetically modified anti-NKG2DLs CAR transduced T cells | NCT05131763 |
| NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia | NKG2D CAR T cells | NCT04658004 |
| Pilot Study of NKG2D CAR-T in Treating Patients with Recurrent Glioblastoma | Recurrent Glioblastoma | NKG2D CAR T cells | NCT04717999 |
| alloSHRINK—Standard cHemotherapy Regimen and Immunotherapy with Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | Unresectable Metastatic Colorectal Carcinoma | Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells, 5-FU, leucovorin, oxaliplatin, irinotecan | NCT03692429 |
| Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | Acute Myeloid Leukemia, Multiple Myeloma Myelodysplastic Syndrome |
NKG2D CAR T cells | NCT02203825 |
| Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours | Solid Tumors | CAR-NK Cells followed by IL-2 injection | NCT03415100 |
| Immunotherapy of CD8+ NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | CD8+, NKG2D+, AKT cells, Gemcitabine | NCT02929797 |
| NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors | Solid Tumor, Hepatocellular Carcinoma, Colorectal Carcinoma, Glioma |
Autologous genetically modified anti-NKG2DLs CAR transduced T cells | NCT04550663 |
| Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma | Myeloma, Transplant Eligible Patients | Cytotoxic T-cells, IL-2, GM-CSF | NCT00439465 |
| Novel Gamma-Delta (γδ) T Cell Therapy for Treatment of Patients with Newly Diagnosed Glioblastoma (DRI) | Glioblastoma | Gene modified drug resistant immunotherapy (γδT Cell) administered | NCT04165941 |